Eye care products recalled nationwide as customers warned to stop use ‘immediately'
Nearly two million cartons of eyedrops have been recalled due to concerns about quality.
BRS Analytical Service, LLC announced the urgent recall of five eye care products, healthcare distributor AvKARE shared in a recent press release.
The recall comes after a Food and Drug Administration (FDA) audit identified violations of Current Good Manufacturing Practice (CGMP).
CGMP regulations for drugs contain minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packing of a drug product.
Although it's unclear what health risks may be posed, CGMP deviations could lead to 'unacceptable quality' of the recalled eyecare solutions, and it's 'not possible to rule out patient risks resulting from use of these products,' according to AvKARE.
The five solutions that have been recalled are Artificial Tears Ophthalmic Solution, Carboxymethylcellulose Sodium Ophthalmic Gel 1%, Carboxymethylcellulose Sodium Ophthalmic Solution, Lubricant Eye Drops Solution, and Polyvinyl Alcohol Ophthalmic Solution.
Eye solutions were shipped from May 26, 2023, until April 21, 2025. Consumers are being asked to fill out the 'Quantity to Return' section and the customer information block on the recall notice, which can be faxed or emailed to AvKARE. People are urged to submit the forms even if they don't have the recalled eyecare solutions anymore.
Consumers should throw away these products immediately or return them to the place of purchase to get a full refund. You can find a list of all the eyecare products that were a part of this recall here.
According to the FDA, the recall was also issued due to a 'lack of assurance of sterility' in these products. The recall affects more than 1.8 million cartons of eye drops.
On May 6, the recall was identified as a Class II one, which is 'a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death,' according to the FDA.
The eyecare solutions are one of many everyday products that have been recalled in 2025. Earlier this month, popular wellness brand Optimal Carnivore issued a voluntary recall on 1,500 bottles of their Bone & Joint Restore capsules, after they were distributed nationwide through major retailers, such as Amazon.
The capsules, which contain bone marrow and bones from cows, were recalled due to potential salmonella contamination. Salmonella infection is a common bacterial disease that can affect the intestinal tracts and occurs after drinking contaminated water, eating raw meat, poultry, eggs, or unpasteurized milk.
In March, the FDA announced a recall of 1,068 bottles of Henkel's Tec Italy Totale Shampoo because they may contain the bacteria Klebsiella oxytoca, which can cause infections in the eyes, nose, and skin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Weaver Nut Company recalls chocolate nonpareils over undeclared allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds)Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk. Saturday Sessions: Grace Potter performs "Paris" Saturday Sessions: Grace Potter performs "Medicine" Saturday Sessions: Grace Potter performs "Before the Sky Falls"
Yahoo
3 hours ago
- Yahoo
Weaver Nut Company recalls chocolate nonpareils over undeclared allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds)Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk. Saturday Sessions: Grace Potter performs "Paris" Saturday Sessions: Grace Potter performs "Medicine" Saturday Sessions: Grace Potter performs "Before the Sky Falls"
Yahoo
9 hours ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
